Skip to content

Investor Relations / Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting

Jun 7, 2019

Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting

Approximately 10 Million People with Diabetes Are at Elevated Risk of Cardiovascular Disease1,2

In a release issued under the same headline earlier today by Amarin Corporation plc (NASDAQ: AMRN), please note the copy has been updated to directly focus on Amarin’s presentations for the 2019 ADA conference. The corrected release follows:

BEDMINSTER, N.J. and DUBLIN, Ireland, June 07, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that three Amarin-supported posters will be presented at the American Diabetes Association 79th Scientific Sessions in San Francisco, June 7 – 11, 2019.  All three posters highlight important findings regarding the challenges of current treatment options for diabetes patients with cardiovascular risks.  More than 30 million adults in the United States have diabetes, 10 million of whom are considered at elevated risk for cardiovascular events, despite being on cholesterol-management medicines.1,2

“We have learned through research that cholesterol and diabetes management is not enough to effectively treat cardiovascular disease in patients with diabetes and other risk factors,” said Craig Granowitz, M.D., Ph.D., chief medical officer of Amarin.  “Cardiovascular disease is the No. 1 cause of death in people with diabetes. We applaud the ADA for highlighting the need to better understand and address increased cardiovascular risk in patients with diabetes.”

Amarin-Supported Research to be Presented at the ADA Scientific Sessions

Poster Presentations

Association Between Triglycerides and Residual Cardiovascular (CVD) Risk in Patients with Type 2 Diabetes and Established CVD: An Analysis of the BARI2D Trial, Abstract 1472-P, Embargoed Until Saturday, June 8, 10 a.m. (Pacific Time).

  • Neha J. Pagidipati, M.D., MPH; Ann Marie Navar, M.D., Ph.D.; Hillary Mulder, M.S.; Daniel Wodjyla, M.S.; Sephy Philip, RPh, PharmD; Craig Granowitz, M.D., Ph.D.; Eric D. Peterson, M.D., MPH.

Long-term Statin Persistence is Poor Among High-Risk Patients with Baseline Diabetes: A Real-World Administrative Claims Analysis of the Optum Research Database, Abstract 616-P, Embargoed Until Saturday, June 8, 10 a.m. (Pacific Time),

  • Peter P. Toth, M.D., Ph.D., Craig Granowitz, M.D., Ph.D. Michael Hull, MS; Sephy Philip, RPh, PharmD.

Moderated Poster Session
Eicosapentaenoic Acid (EPA) Inhibits Human HDL Oxidation in a Concentration-Dependent Manner at a Pharmacologic Dose in Vitro, Abstract 612-P; Embargoed Until Saturday, June 8, 10 a.m.presented in poster sessions at 10 a.m. (Pacific Time) (New Concepts in Lipidology); Monday, June 10, noon (Pacific Time) (General Poster Session)

  • Samuel, C.R. Sheratt, B.S.; R. Preston Mason Ph.D.

About Amarin

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription in the United States, Lebanon and the United Arab Emirates. Amarin’s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East. For more information about Amarin, visit www.amarincorp.com.

About Cardiovascular Disease 

Worldwide, cardiovascular disease (CVD) remains the No. 1 killer of men and women. In the United States, CVD leads to one in every three deaths – one death approximately every 38 seconds – with annual treatment cost in excess of $500 billion.3,4

Multiple primary and secondary prevention trials have shown a significant reduction of 25% to 35% in the risk of cardiovascular events with statin therapy, leaving significant persistent residual risk despite the achievement of target LDL-C levels.5

Beyond the cardiovascular risk associated with LDL-C, genetic, epidemiologic, clinical and real-world data suggest that patients with elevated triglycerides (TG) (fats in the blood), and TG-rich lipoproteins, are at increased risk for cardiovascular disease. 6,7,8,9

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

References 

Fan W, Philip S., Granowitz C, Toth P, Wong N. Prevalence and Predictors of Residual Hypertriglyceridemia According to Statin Use in US Adults with Diabetes. Presented at the American Diabetes Association Scientific Sessions, June 22-26, 2018, Orlando, Florida

2 Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. J Clin Lipidol. 2019;13(1):100-108.

American Heart Association. 2018. Disease and Stroke Statistics-2018 Update.

American Heart Association. 2017. Cardiovascular disease: A costly burden for America projections through 2035.

Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.

Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016; 118:138-145.

Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15): e008740.

Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016; 118:547-563.

Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014; 384:626–635.

Amarin Contact Information

Media Inquiries: 
Gwen Fisher 
Corporate Communications
Amarin Corporation plc
In U.S.: +1 (908) 325-0735
pr@amarincorp.com

Investor Inquiries:
Elisabeth Schwartz
Investor Relations 
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com

Lee M. Stern
Trout Group 
In U.S.: +1 (646) 378-2992 
lstern@troutgroup.com

Amarin Corporation plc Logo

 

Source: Amarin Corporation plc

Amarin Corporation